參考文獻 |
1.Agresti, A. (1990). Categorical Data Analysis, John Wiley & Sons.
2.Bradstreet, T.E. and Liss, C. L. (1995). Favorite Data Sets from Early (and Late) Phases of Drug Research - Part 4. Proceedings of the Section on Statistical Education of the American Statistical Association. 335-340.
3.Bretagnolle, J. and Huber-Carol, C. (1988). Effects of omitting covariates in Cox’s model for survival data. Scand. J. Statist. 15, 125-138.
4.Bretz, F., Hothorn A. L. and Hsu, J. C. (2003). Identifying effective and/or safe doses by stepwise confidence intervals for ratios. Statistics in Medicine 22, 847-858.
5.Lagakos, S. W. and Schoenfeld, D. A. (1984). Properties of proportional-hazards score tests under misspecified regression models. Biometrics 40, 1037-1048.
6.Marcus, R., Gabriel, K. R. and Peritz, E. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63, 655-660.
7.Morgan, T. M. (1986). Omitting covariates from the proportional hazard model. Biometrics 42, 993-995.
8.Tamhane, A. C., Dunnett C. W., Green J. W. and Wetherington, J. D. (2001). Multiple test procedures for identifying the maximum safe dose. Journal of American Statistical Association 96, 835-843.
9.Tukey, J. W., Ciminera, J. L. and Heyse, J. P. (1985). Testing the statistical certainty of a response with increasing doses of a compound. Biometrics 41, 295-301.
10.Yanagawa, T., Kikuchi, Y. and Brown, K. G. (1977). No-observed-adverse-effect levels in severity data. Journal of American Statistical Association 92, 449-454. |